Advertisement

Expression ofHer2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma

  • J. Jaehne
  • C. Urmacher
  • H. T. Thaler
  • H. Friedlander-Klar
  • C. Cordon-Cardo
  • H. J. Meyer
Original Papers Clinical Oncology

Summary

The expression of theHer2/neu gene product p 185 was retrospectively analyzed in 58 patients with gastric carcinoma. The results were correlated to various clinicopathological and prognostic factors. Positive membrane staining for p185 could be detected in 38% of the patients (22/58). Membrane staining was significantly greater in well and moderately differentiated tumors of the intestinal type when compared with poorly differentiated lesions and carcinomas of the diffuse type (P<0.01). Positive membrane staining did not correlate with site and tumor stage, but T1 lesions had less membrane staining than more advanced primary tumors. Overall survival showed no difference between p185-positive and negative cases. Multivariate analysis defined a subgroup of curatively resected patients with stage III and IV disease that had a statistically significant poorer survival when p185 was overexpressed (P=0.005). Overexpression of theHer2/neu product p185 appears to be associated with intestinal-type gastric carcinoma and may sociated with intestinal-type gastric carcinoma and may help in identifying a subset of patients at increased risk for shorter survival.

Key words

Her2/neu oncogene product p185 Gastric carcinoma Clinicopathological variables Prognosis 

Abbreviations

PBS

phosphate-buffered saline

BSA

bovine serum albumin

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-er B-2 gene: a 185-kilodalton glycoprotein with typrosine kinase activity. Science 232:1644–1646Google Scholar
  2. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE (1988) Corrleation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238–1243Google Scholar
  3. Clark GM, McGuire WL (1991) Follow-up study ofHer2/neu amplification in primary breast cancer. Cancer Res 51:944–948Google Scholar
  4. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, Richter King C, Aaronson SA (1987).ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–182Google Scholar
  5. Falck VG, Gullick WJ (1989) c-erb B-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. J Pathol 159:107–111Google Scholar
  6. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767Google Scholar
  7. Fukushige SI, Matsubara KI, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K, Yamamoto T (1986) Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 6:955–958Google Scholar
  8. Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shiloh Y (1989) Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance. Int J Cancer 44:802–805Google Scholar
  9. Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen DP, Chaganti RSK (1990) Gene amplification in gastric and esophageal adenocarcinoma. Cancer Res 50:6417–6422Google Scholar
  10. Hsu SM, Raine L, Fauger H (1981) Comparative study of the peroxidase-antiperoxidase and avidin-biotin complex method for studying polypeptide hormones with radioiummunoassay antibodies. Am J Pathol 75:734–740Google Scholar
  11. Jaehne J, Meyer HJ, Maschek H, Geerlings H, Bruns E, Pichlmayr R (1992) Lymphadenectomy in gastric carcinoma—a prospective and prognostic study. Arch Surg 127:290–294Google Scholar
  12. Kameda T, Yashi W, Yoshida K, Tsujino T, Nakayama H, Ito M, Ito H, Tahara E (1990) Expression of ERBB2 in human gastric carcinomas: relationsship between p185ERBB2 expression and the gene amplification. Cancer Res 50:8002–8009Google Scholar
  13. Laurén P (1965) The two histolocial main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31–49Google Scholar
  14. Lundegardh G, Asami HO, Malker B (1986) Gastric cancer survival in Sweden. Ann Surg 204:546–551Google Scholar
  15. Lupu R, Colomer R, Zugmeier G, Sarup J, Shepard M, Slamon D, Lippman ME (1990) Direct interaction of a ligand for theerbB2 oncogene product with the EGF receptor and p185erbB2. Science 249:1552–1555Google Scholar
  16. Masood S, Barker EA, Barnes RE (1991)Her2/neu oncogene protein and prognosis in gastric adenocarcinoma. Mod Pathol 4:38AGoogle Scholar
  17. Nanus DM, Kelsen DP, Niedzwiecki D, Chapman D, Brennan M, Cheng E, Melamed M (1989) Flow cytometry as a predictive indicator in patients with operable gastric cancer. J Clin Oncol 7:1105–1112Google Scholar
  18. Oda N, Tsujino T, Tsuda T, Yoshida K, Nakayama H, Yasui W, Tahara E (1990) DNA ploidy pattern and amplification of ERBB and ERBB2 genes in human gastric carcinomas. Virchows Arch [B] 58:273–277Google Scholar
  19. Oota K, Sobin LH (1977) Histological typing of gastric and oesophageal tumors. International histological classification of tumors. WHO, Geneva, no. 18Google Scholar
  20. Ovaska J, Kruuna I, Saario I, Schröder T, Lempinen M (1989) Surgical treatment of gastric carcinoma. Am J Surg 158:467–471Google Scholar
  21. Pavelic ZP, Petrelli NJ, Herrera L, Vaugham MM, Paecock JS, Pavelic L (1990) D-14 monoclonal antibody to carcinoembryonic antigen: immunohistochemical analysis of formalinfixed, paraffin-embedded human colorectal carcinoma, tumors of non-colorectal origin and normal tissues. J Cancer Res Clin Oncol 116:51–56Google Scholar
  22. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA (1984) Theneu oncogene: anerb-B-related gene encoding a 185,00-Mr tumor antigen. Nature 312:513–516Google Scholar
  23. Shiu MH, Moore E, Sanders M, Huvos A, Freedman B, Goodbold J, Chaiyaphruk S, Wesdorp R, Brennan MF (1987) Influence of the extent of resection on survial after curative treatment of gastric carcinoma. Arch Surg 122:1347–1351Google Scholar
  24. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of theHer2/neu oncogene. Science 235:177–182Google Scholar
  25. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989a) Stdies of theHer2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712Google Scholar
  26. Slamon DJ, Press MF, Godolphin W, Ramos L, Haran P, Shek L, Stuart SG, Ullrich A (1989b) Studies of theHer2/neu oncogene in human breast cancer. Cancer Cells 7:371–384Google Scholar
  27. Tal M, Wetzler M, Josefberg Z, Gutman M, Assaf D, Kris R, Shiloh Y, Givol D, Schlessinger J (1988) Sporadic amplification of theHer2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 48:1517–1520Google Scholar
  28. UICC (1987) TNM classification of malignant tumors, 4th edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  29. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R (1988). Neu-protein overexpression in breast cancer. N Engl J Med 319:1239–1245Google Scholar
  30. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, Lanz L, Meyer J, Siewert JR, Geerlings H, Köhne-Wömpner CH, Harstrick A, Schmoll HJ (1990) New developments in the treatment of gastric carcinoma. Semin Oncol 17:61–70Google Scholar
  31. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K (1986) Similarity of protein encoded by human c-erbB-2 gene to epidermal growth factor receptor-related protein. Nature 319:230–234Google Scholar
  32. Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H, Cline MJ (1986) Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1:765–767Google Scholar
  33. Yokota J, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H, Yoshida T, Terada M, Sugimura T (1988) Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erb A homologue. Oncogene 2:283–287Google Scholar
  34. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M, Sasaki T (1991a) Evaluation of immunoreactivity forerbB-2 protein as a maker of poor short term prognosis in gastric cancer. Cancer Res 51:1034–1038Google Scholar
  35. Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, Kosaka T, Miwa K, Miyazaki I, Endou Y, Tanaka M, Sasaki T (1991b) Expression of c-erbB-2 oncoprotein in gastric carcinoma. Cancer 67:2914–2918Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • J. Jaehne
    • 1
  • C. Urmacher
    • 2
  • H. T. Thaler
    • 3
  • H. Friedlander-Klar
    • 3
  • C. Cordon-Cardo
    • 2
  • H. J. Meyer
    • 1
  1. 1.Clinic for Abdominal and Transplantation SurgeryMedical School HannoverHannover 61Germany
  2. 2.Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.Department of BiostatisticsMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations